IVVD Quote, Financials, Valuation and Earnings

ADMA Biologics, Inc. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of 27.14%. Invivyd, Inc.'s return on equity of -87.85% beat ADMA Biologics, Inc.'s return on equity of 58.71%.

Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 320.17%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 39.95%. Given that Invivyd, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Invivyd, Inc. is more attractive than ADMA Biologics, Inc..

Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.466, suggesting its less volatile than the S&P 500 by 53.393%.

Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.

Invivyd, Inc. quarterly revenues are $13.1M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Invivyd, Inc.'s net income of -$10.5M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 21.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 6.30x versus 9.23x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cidara Therapeutics, Inc. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of -30201.66%. Invivyd, Inc.'s return on equity of -87.85% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.

Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 320.17%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.05%. Given that Invivyd, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Invivyd, Inc. is more attractive than Cidara Therapeutics, Inc..

Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.523, suggesting its more volatile than the S&P 500 by 52.269%.

Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.

Invivyd, Inc. quarterly revenues are $13.1M, which are larger than Cidara Therapeutics, Inc. quarterly revenues of --. Invivyd, Inc.'s net income of -$10.5M is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 6.30x versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of 10.24%. Invivyd, Inc.'s return on equity of -87.85% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 320.17%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 3.88%. Given that Invivyd, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Invivyd, Inc. is more attractive than Amicus Therapeutics, Inc..

Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.

Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Invivyd, Inc. quarterly revenues are $13.1M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Invivyd, Inc.'s net income of -$10.5M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 6.30x versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Relmada Therapeutics, Inc. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of --. Invivyd, Inc.'s return on equity of -87.85% beat Relmada Therapeutics, Inc.'s return on equity of -214.4%.

Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 320.17%. On the other hand Relmada Therapeutics, Inc. has an analysts' consensus of $6.67 which suggests that it could grow by 63.4%. Given that Invivyd, Inc. has higher upside potential than Relmada Therapeutics, Inc., analysts believe Invivyd, Inc. is more attractive than Relmada Therapeutics, Inc..

Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Relmada Therapeutics, Inc. has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.834%.

Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relmada Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd, Inc. pays -- of its earnings as a dividend. Relmada Therapeutics, Inc. pays out -- of its earnings as a dividend.

Invivyd, Inc. quarterly revenues are $13.1M, which are larger than Relmada Therapeutics, Inc. quarterly revenues of --. Invivyd, Inc.'s net income of -$10.5M is lower than Relmada Therapeutics, Inc.'s net income of -$10.1M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while Relmada Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 6.30x versus -- for Relmada Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.